Firebrick Pharma Ltd Sustainability Reports
Firebrick Pharma Limited is an Australian pharmaceutical developer focused on the development and commercialization of innovative povidone-iodine nasal formulations under the Nasodine brand, primarily targeting treatments for respiratory infections like the common cold.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
FIGI: BBG0140SS6W9
3 reports from 2022 to 2024
